Page 44 - Priority Review News Today

CHAPLE is an ultra-rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms Approval represents 10th FDA-approved medicine invented by...

The FDA has granted Priority Review for the supplemental New Drug Application for Tarpeyo (budesonide) seeking full approval in the treatment of IgA nephropathy.

The FDA has granted Priority Review for Tibsovo (ivosidenib) in the treatment of IDH1-mutated relapsed or refractory myelodysplastic syndromes.

Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in the Treatment of IDH1-mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS) If approved, TIBSOVO will be the first and only approved targeted therapy for MDS patients with a susceptible IDH1 mutat...

RHB-107 included in the U.S. Department of Defense-supported ACESO PROTECT multinational platform trial for early COVID-19 outpatient treatment; The...

The Food and Drug Administration granted a priority review to Tibsovo for the treatment of patients with IDH1-mutant relapsed or refractory myelodysplastic syndrome.

Repotrectinib continued to demonstrate high response rates and durable responses, including robust intracranial responses, in patients with ROS1-positive locally advanced or metastatic non-small cell... -Today at 10:20 am- MarketScreener

Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, fibrodysplasia...

Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, fibrodysplasia ossificans progressiva FOP impacts about 400... -Today at 03:33 pm- MarketScreener

(RTTNews) - bluebird bio, Inc. (BLUE) announced the FDA has communicated that an advisory committee meeting will not be scheduled for lovotibeglog...